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ABSTRACT 
Introduction: The treatment of cutaneous leishmaniasis is toxic, has contraindications and 
a high cost. 
Objective: To estimate the cost-effectiveness of thermotherapy versus pentavalent 
antimonials for the treatment of cutaneous leishmaniasis. 
Methods: Effectiveness was the proportion of healing, and safety with the adverse effects; 
these parameters were estimated from a controlled clinical trial and a meta-analysis. A 
standard costing were conducted. Average and incremental cost-effectiveness ratios were 
estimated. The uncertainty regarding effectiveness, safety and costs was determined through 
sensitivity analyses. 
Results: The total costs were $66,807 with Glucantime and $14,079 with thermotherapy. 
The therapeutic effectiveness rates were 64.2% for thermotherapy and 85.1% for Glucantime. 
The average cost-effectiveness ratios ranged between $721 and $1,275 for Glucantime and 
between $187 and $390 for thermotherapy. Based on the meta-analysis thermotherapy may 
be a dominant strategy. 
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Conclusion: The excellent cost-effectiveness ratio of thermotherapy shows the relevance of 
its inclusion in guidelines for the treatment. 
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INTRODUCTION 
 
Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania, family 
Trypanosomatidae, with three main clinical forms: cutaneous, mucosal and visceral. From 
an epidemiological standpoint, the disease is characterized by being endemic in 99 countries. 
A total of 12 million infections, with 2 million incident cases per year, are estimated. 
Regarding visceral leishmaniasis, the estimated lethality rate is 10%, with between 20,000 
and 40,000 deaths per year. These figures are underestimated due to under-diagnosis, the lack 
of active surveillance, the high number of asymptomatic infections, and the fact that most 
endemic countries do not have a mandatory notification system (1-4). 
Cutaneous leishmaniasis is the most frequent worldwide; 75% of cases occur in Afghanistan, 
Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan and Peru (4). This form of the 
disease characteristically starts with papules that become nodules and ulcers, which are 
related to disability, scars, stigmatization, psychosocial problems and economic losses from 
an inability to work and lost work days (1,5,6). 
The standard treatment of cutaneous leishmaniasis is based on pentavalent antimonials, 
mainly sodium stibogluconate (Pentostam ®) and meglumine antimoniate (Glucantime ®), 
although there are various therapeutic resources, such as thermotherapy and topical, local 
and systemic treatments (7). Treatment with pentavalent antimonials has been questioned 
due to the recording of multiple adverse consequences, such as cardiac, liver, kidney and 
hematological toxicity, sometimes leading to patient death, pancreatitis, myalgia and 
arthralgia, along with problems of therapeutic adherence (8, 9). Antimonial treatment is 
contraindicated in multiple populations, such as infants, pregnant women and children and 
in patients with chronic problems, and contraindicated due to the high cost associated with 
the treatment itself and the management of the medication’s side effects (10-19). 
Faced with the above problems, multiple local treatments have been explored, among which 
thermotherapy stands out due to certain advantages, such as the low number of adverse 
effects and contraindications and good adherence; it is safer than pentavalent antimonials, as 
it results in fewer side effects and has good effectiveness in empirical applications in rural 
communities, controlled clinical trials and meta-analyses (20-26). In addition, thermotherapy 
significantly reduces the cost entailed in the management of cutaneous leishmaniasis for the 
Social Security Health System. The cost per patient with Glucantime (treatment of choice) is 
$38, whereas the cost is less than $20 with thermotherapy (2). However, it is clear that these 
values do not include the cost of personnel, diagnostic aids, and other resources required to 
provide treatment and to monitor patient safety. 
The background outlined above supports the hypothesis that thermotherapy may be the most 
cost-effective strategy for the treatment of cutaneous leishmaniasis, as it has a similar 
therapeutic effectiveness but with significantly lower costs. Indeed, unlike the first-line 
treatment, its implementation does not include diagnostic aids, such as electrocardiograms 
and laboratory tests for hematological, kidney, pancreatic and liver profiles. Thermotherapy 
requires fewer visits by the medical team and reduces the costs associated with the 
management of adverse effects of pentavalent antimonials. 
Notwithstanding the above, a full economic assessment for thermotherapy in the treatment 
of cutaneous leishmaniasis has not been conducted; based on a review of economic 
assessments, the lack of research on this topic was corroborated. In this regard, a search on 
EBM Reviews - NHS Economic Evaluation Database generated eleven results on 
leishmaniasis, two of which do not correspond with economic assessments; the remaining 
nine were based on comparing the cost of medication against the visceral form of the disease 
(27), costs of active case detection (28), cost-effectiveness analysis of prevention strategies 
(6), analysis of the combination of therapies for visceral leishmaniasis in India (29,30), the 
implementation of a treatment program against the cutaneous form of the disease (31), a 
medication policy against the visceral form of leishmaniasis (32), a vaccine for the visceral 
form in India (33), and a vaccine for cutaneous leishmaniasis in seven American countries 
(34). From this search, it was concluded that in the economic assessments on leishmaniasis, 
seven correspond to cost-effectiveness studies, only two assessments were conducted on the 
cutaneous form, three have compared treatments, and none have analyzed thermotherapy. 
This search was extended to PubMed, ScienceDirect, Web of Science, Wiley, Scielo, Lilacs 
and OVID, with the inclusion criterion that the terms "Cutaneous leishmaniasis" & 
"Thermotherapy" were in the title, abstract or keywords; but no difference in results was 
observed. 
The aim of this research was to estimate the cost-effectiveness ratio of thermotherapy 
compared with pentavalent antimonials for the treatment of cutaneous leishmaniasis in 
Colombia from an institutional standpoint. 
  
MATERIAL AND METHODS 
Type of study: Cost-effectiveness analysis. 
PICO question: Population, Intervention, Comparison, Outcome (8). 
Population: Soldiers from five health centers of the armed forces of Colombia in the 
Northeast, South and Central regions of the country, with confirmed diagnosis of cutaneous 
leishmaniasis, without mucosal involvement, without previous treatment for this infection, 
and with normal kidney, liver and hematological function tests, were included in this study. 
Patients with comorbidities, with ten or more lesions, and with involvement of sites close to 
the nasal or oral mucosa, eyes and anal or urogenital openings (less than 2 cm) were excluded. 
A total of 255 patients participated and were randomly assigned to each arm of the study 
based on a calculation of the sample size with effectiveness rates of 78% for thermotherapy 
and 90% for meglumine antimoniate, a confidence interval of 95%, a power factor of 80%, 
and a sampling correction of 20% (8). 
In addition, the population of eight studies of a meta-analysis of controlled clinical trials 
assessing the effectiveness of thermotherapy in the treatment of cutaneous leishmaniasis (26) 
was included in this study. 
Intervention: Thermotherapy involved the local application of heat (radiofrequency) at 50°C 
for 30 seconds three times a week (or more depending on the lesion) using ThermoMed® 
(Thermosurgery Inc., Phoenix, AZ, USA) on the active center and edges until the entire 
lesion was covered. Prior asepsis and local anesthesia were applied with Xylocaine 2%, 
followed by fusidic acid treatment for 10 days (8). 
Comparison: Pentavalent antimonials, sodium stibogluconate and meglumine antimoniate. 
Outcomes: The primary outcome was effectiveness or proportion of cured patients, i.e., with 
the disappearance or re-epithelialization of lesions and complete loss of indurated lesions 
until three months after treatment ended, without reactivation of the lesion or appearance of 
mucosal involvement for six months following the completion of treatment. The secondary 
outcomes included data on treatment safety, consisting of local side effects, such as pain, 
burning, itching, erythema, edema and swelling at the site of administration, and systemic 
side effects, such as myalgia, fever, anorexia; headache, arthralgia, generalized rash, and 
laboratory abnormalities in blood counts, blood chemistry and liver function tests (8). 
Analytical decision model: The decision tree presents different clinical courses that can 
occur with both treatments. The first tree includes the comparison of therapeutic 
effectiveness; a binary result of cure or therapeutic failure is presented in the following tree. 
Where a failure occurred, a rescue treatment with meglumine antimonate was provided 
according to the guidelines for treatment of leishmaniasis of the Ministry of Health of 
Colombia. The decision tree is finalized at that point because the probability of failure in a 
second rescue treatment approaches zero. The assessment of secondary outcomes was 
performed for every decision node and at the end of each possible course of action described 
in Figure 1. 
The safety analysis assessed adverse effects according to the Common Terminology Criteria 
for Adverse Events v.3 (CTCAE) (35). It should be noted that in the thermotherapy arm, 
there are no systemic effects attributable to the treatment; however, they were included in 
this assessment so as not to skew the monitoring of those effects within the clinical trial. 
Data sources: A secondary data source was used to measure the effectiveness and safety of 
the intervention; the data were collected from a randomized controlled phase III clinical trial 
developed by PECET (8). Additionally, the group of researchers performed a meta-analysis 
to provide additional data on the effectiveness of thermotherapy (26). 
The costing was conducted from an institutional perspective through two methods validated 
by two clinical studies: i) Standard costing, including only the prices of the intervention 
(medication, doctor, nurse and diagnostic aids) and the management of side effects (without 
considering costs associated with patients undergoing rescue treatment), and ii) Costing 
based on patient monitoring; this form includes intervention prices, the management of side 
effects, rescue treatments and the management of their adverse effects. 
For myalgia, arthralgia, fever and headache, the price of analgesic and antipyretic treatment 
was included, usually for six days, with three pills of acetaminophen per day. In case of 
abdominal pain, two pills of omeprazole were provided for six or ten days according to the 
patient's symptoms. However, for the treatment of vomiting, nausea, anorexia and diarrhea, 
three pills of metoclopramide for two days and oral rehydration salts three times a day for 
two days were provided. The following were included among systemic effects: the cost of 
tests, such as blood urea nitrogen (BUN); creatinine blood tests for patients with renal effects; 
amylase test for pancreatic effects; aspartate and alanine transaminase tests (AST and ALT) 
for liver effects; and hemoglobin, red blood cells, leukocytes and platelet count for 
hematological effects. However, it should be noted that these tests are normally performed 
to monitor the toxicity of antimonials and to choose a treatment if toxicity occurs. 
Unit prices of standardized pricing manuals for Colombia, such as SOAT (Compulsory 
Traffic Accident Insurance - Seguro Obligatorio de Accidentes de Tránsito) and SISMED 
(Drug Price Information System - Sistema de Información de Precios de Medicamentos), 
were used. In the case of Glucantime, experts who validated the protocol considered that its 
price was higher than the price included in this study. 
The costs were converted to US dollars, estimated from the exchange rate projected for 2013 
of $1 = $1,900 COP, without applying any annual discount rate, given that the time period 
of the study was less than a year. 
 
Cost-effectiveness analysis: The summary measure used for cost-effectiveness analyses was 
the cost-effectiveness ratio, in terms of the average (cost/effects) for each intervention and in 
terms of incremental costs to estimate the additional cost per effectiveness unit reached. 
Incremental Cost Effectiveness Ratio (ICER) = 
ΔC 
= 
A Costs - B Costs 
ΔE A Effectiveness - B Effectiveness 
Sensitivity Analysis: To analyze the inherent uncertainty of the parameters and the way they 
affect the outcomes, one-way and multivariate sensitivity analyses were performed based on 
the limits of the confidence intervals obtained in therapeutic effectiveness and safety, 
whereas price adjustments for the procurement of healthcare services in Colombia were used 
to analyze costs. Four univariate sensitivity analyses were developed i) according to changes 
in the therapeutic effectiveness of the controlled clinical trial (limits of the confidence 
interval), ii) based on the effectiveness reported in the meta-analysis, iii) with the variation 
in the results of safety (proportion of adverse effects), and iv) with the variations in prices 
used in the procurement of health services in Colombia of 25%, 30% and 48%; thus the 
findings shown are adjusted to the reality of the country's payment and procurements (36). 
Subsequently, the multivariate sensitivity analysis was conducted based on the combinations 
of effectiveness, safety and reported costs. 
Ethical aspects: The principles of the Declaration of Helsinki, Resolution 8430 of 1993 of 
the Colombian Ministry of Health, and Resolution 2378 of 2008 were taken into account. 
  
RESULTS 
Cost measurement 
In the group treated with pentavalent antimonials, the costs of the medication, nursing 
assistance, medical checkups and laboratory tests represented a cost of $65,412, with an 
average cost (per patient) of $540.6, whereas the average cost of the management of adverse 
effects was $11.5 (Table 1). 
In thermotherapy, medical consultations and nursing care represented an average cost of 
$99.3, and the management of adverse effects represented an average cost of $5.8. Although 
adverse effects were included as a way to unify the groups of clinical trials, thermotherapy 
does not actually generate them (Table 2). 
In accordance with the above, the total cost of treatment with pentavalent antimonials was 
$66,807.2 (Table 1), and the total cost with thermotherapy was $14,079.2 (Table 2). 
Subsequently, patients receiving rescue therapy were monitored, and costs associated with 
providing Glucantime and managing adverse effects in both groups were added, resulting in 
a total cost of $76,521.6 for the 121 patients who were provided with Glucantime, 18 
individuals who required rescue therapy and one patient who received two rescue treatments 
(Table 1). However, for the 134 patients who received thermotherapy and 48 who required 
rescue treatment, the total cost was $39,981.6 (Table 2). It should be noted that in previous 
studies on leishmaniasis and in other assessments of cost-effectiveness, the costs associated 
with the management of patients with treatment failure were not included. In this sense, if 
the cost of patients who received rescue therapy had not been included, the thermotherapy 
cost-effectiveness ratio would be much better. 
When taking into account the lower limit of the confidence interval of the proportion of 
adverse effects (maximum safety level), a total cost of $66,257.2 was obtained for the group 
treated with pentavalent antimonials, and a total cost of $13,572.1 was obtained for the 
thermotherapy group. In the second scenario, the upper limit of the proportion of side effects 
was taken, so the costs increased to $67,529.3 for the group with pentavalent antimonials and 
to $14,684.3 for the thermotherapy group (Table 3). In addition, according to the percentages 
of procurement of health services in Colombia, the cost of pentavalent antimonials increased, 
ranging between $83,509.0 (25% adjustment) and $98,874.7 (48% adjustment), whereas the 
cost of thermotherapy was between $17,599.1 (25% increase) and $20,837.3 (48% increase) 
(Table 3). 
Safety measures and clinical effectiveness 
In the safety analysis, among the 121 patients treated with pentavalent antimonials, the major 
local effects were 74% vomiting, nausea, anorexia and diarrhea, followed by 55% myalgia, 
54% arthralgia, and 43% headache. The most frequent systemic effects included 20% 
pancreatic disorders and 17% liver disorders (Table 1). Among patients undergoing 
thermotherapy, the proportion of adverse effects was significantly lower, with greater 
occurrences of vomiting, nausea, diarrhea, anorexia and local effects (10%), and the highest 
systemic effects were pancreatic and liver disorders (5%) (Table 2). In patients receiving 
rescue therapy, statistically similar probabilities to those obtained for patients treated with 
pentavalent antimonials were found. 
In terms of therapeutic effectiveness, 48 out of the 134 patients treated with a single 
thermotherapy application showed treatment failure, which is equivalent to 64.2% 
effectiveness (86/134); among the 48 patients who underwent rescue treatment, no treatment 
failures were recorded. Treatment failure was also recorded in 18 patients treated with 
pentavalent antimonials, equivalent to 85.1% effectiveness (103/121). Among those who 
underwent rescue treatment, one case of therapeutic failure occurred. Table 3 shows the 
results of therapeutic effectiveness, as described in the previous paragraph, with the 
minimum and maximum values of their 95% confidence intervals. Additionally, therapeutic 
effectiveness was calculated in a meta-analysis conducted by researchers on thermotherapy 
and pentavalent antimonials (26). 
Cost-effectiveness ratio and sensitivity analysis 
The average cost-effectiveness ratio derived in the standard costing was $785.0 for 
pentavalent antimonials and $219.3 for thermotherapy. Based on the univariate and 
multivariate sensitivity analyses, the variation for pentavalent antimonials ranged between 
$721.0 and $1,274.8, whereas the average cost-effectiveness ratio for thermotherapy ranged 
from US $186.7 to US $390.2 (Table 4). 
On the basis of the costing per patient (which, unlike the standard costing, includes costs 
associated with rescue treatments), the average cost-effectiveness ratios were $632.4 
(ranging from $590.7 to $721.1) for prevalent antimonials and $298.4 (ranging from $245.9 
to $352.2) for thermotherapy. The incremental cost-effectiveness ratio was $2,523 (ranging 
from $2,323 to $4,073) (Table 4). 
In the sensitivity analyses, the final decision is subject to the cost-effectiveness threshold 
established by the authorities in charge of assigning the intervention, in this case the Ministry 
of Health and Social Protection (Ministerio de Salud y de Protección Social). In this sense, 
if a threshold of $400 per patient treated is set, all of the combinations of costs and 
effectiveness and the safety measures analyzed provide a basis for concluding that 
thermotherapy is more cost-effective than treatment with pentavalent antimonials. 
It is worth mentioning that when using the meta-analysis data in which pentavalent 
antimonials and thermotherapy were similar in terms of effectiveness, the incremental cost-
effectiveness ratio showed a negative result, given that thermotherapy showed an incremental 
cost of $52,728.0 (lower incremental cost than pentavalent antimonials) and an incremental 
therapeutic effectiveness of 2.6%. This finding indicates that the increasing effectiveness of 
thermotherapy in a percentage compared with pentavalent antimonials may generate cost 
savings between $40,560 and $43,940. In other words, thermotherapy is a dominant strategy, 
as it has a lower cost and a slightly higher therapeutic effectiveness (Table 4). The sensitivity 
analysis indicated that the conclusion is robust under variations in the assessed parameters, 
namely effectiveness, safety and costs. 
 
DISCUSSION 
In this study, data were collected regarding thermotherapy effectiveness from the clinical 
trial of López et al. (8) and a meta-analysis (26). Both studies concluded that this therapy 
could be applied to patients with cutaneous leishmaniasis, which is consistent with studies 
that have shown favorable results of the use of heat or caustic treatments in Latin American 
rural and indigenous populations (23-25). Furthermore, thermotherapy effectiveness gains 
greater relevance in the treatment of the cutaneous form of the disease, as the following 
advantages are given: shorter duration; greater adherence (37); does not require paraclinical 
examinations; and can be used in patients with kidney, liver or heart problems, in pregnant 
women, children and other groups in which pentavalent antimonials or miltefosine are 
contraindicated (38). Moreover, in the systemic therapy, effectiveness can be reduced, and 
resistance based on incomplete administration or poor adherence can grow day by day (21). 
Despite the existing evidence of the effectiveness and safety of thermotherapy in the 
treatment of cutaneous leishmaniasis and the fact that this is the most prevalent form of the 
disease in the world, most studies from an economic standpoint have focused on the visceral 
form of the disease. The economic analyses conducted on cutaneous leishmaniasis differ 
from those developed in this study; therefore, it is difficult to make a comparison of the cost-
effectiveness found. However, it is worth mentioning the results of the following research 
studies: i) Orellana et al. in Argentina found an incremental cost-effectiveness ratio of 
$156.46 per DALY (Disability Adjusted Life Years) avoided for an early diagnosis strategy 
and a ratio of $13,155.52 per DALY avoided for the use of clothes and curtains impregnated 
with insecticide (6), ii) Vega J et al., in 1 524 patients treated with intramuscular antimonials 
during an outbreak in Colombia, reported a cost per patient treated and cured with 
antimonials in US$ 345 (CI 277-488) and the cost for DALY avoided in US$ 15 215 (IC 12 
226 to 21 532) (41), and iii) Reithinger R et al., reported a cost of standard treatment US $ 
27 (IC 20-36) per patient cured and US $ 1,200 (761 - 1827) per DALY avoided (31). 
However, the World Health Organization no longer considers Meglumine Antimoniate as a 
treatment of choice for this clinical form of the disease. 
Unlike other economic assessments on leishmaniasis, final outcomes such as mortality or 
DALYs were not used in this research for the following reasons: low lethality from the 
cutaneous form of the disease and inherent difficulties in estimating DALYs. Indeed, these 
metrics were used in leishmaniasis on the basis of an extrapolation of the measurement of 
disability resulting from diseases such as leprosy (6). The metrics were also used for taking 
arbitrary measures on the duration of the disease, similar to some previous studies that 
estimate DALYs as the product of the incidence, the disability weight for cutaneous 
leishmaniasis (taken from a global report and not from a unique context), and disease duration 
(31). Instead, the cure proportion was used as an outcome, as this measure directly reflects 
the epidemiological features of the disease. 
However, the treatment of cutaneous leishmaniasis has wide variations in cost due to the 
price of the medication, the protocol of application (intralesional or intramuscular, the latter 
being approved by the Ministry of Health of Colombia), the type of patient care (31) and the 
social security system to which the patient belongs. To tackle this contingency, this study 
took a wide range of costs, and the sensitivity analysis showed the model robustness to 
establish the greater cost-effectiveness of thermotherapy. In this vein, research studies that 
have recommended the use of pentavalent antimonials for their low cost generally do not 
include costs associated with the management of adverse effects (32). 
In the case of equipment not included in the costing guides, there are challenges about how 
to include in the algorithm the estimation of the costs of every health unit currently providing 
treatment for CL with Anitmonials would need to invest have their own ThemoMed machine. 
The cost of ThemoMed is just one time payment, however it is an initial cost that need to be 
include to convince the health regulators that even when at the beginning the cost of using 
thermotherapy is going to probably higher, this cost is going to be dramatically less for the 
subsequent years. In relation to this possible limitation must bear in mind that the sensitivity 
analysis shows that changes in cost parameters do not affect the conclusion. 
According to the sensitivity analyses, the average cost-effectiveness ratios ranged from 
$590.7 to $1,274.8 for pentavalent antimonials and from $186.7 to $390.2 for thermotherapy; 
the incremental cost-effectiveness ratio was $2,523 (range from $2,323 to $4,073). This ratio 
is subject to the threshold set by the decision maker; in this regard, the WHO has indicated 
that a strategy is very cost-effective when cost-effectiveness is lower than the gross domestic 
product (GDP) per capita in the country and is cost-effective when cost-effectiveness is lower 
than three times the GDP per capita, while higher values are not considered cost-effective 
(39). In the current study, we found a cost-effectiveness ratio close to one-third of the GDP 
per capita, which was $7,826 in Colombia in 2013 (40). This finding qualifies thermotherapy 
as a highly cost-effective strategy for the treatment of cutaneous leishmaniasis in all scenarios 
generated in the sensitivity analysis, that is, the same conclusion is found when individually 
and simultaneously changing the costs, safety and effectiveness of the assessed treatments. 
Several motives have expanded the use of cost-effectiveness analyses according to the WHO: 
i) to prioritize the funding of interventions, to reduce health inequalities and to address the 
wellbeing of future generations, ii) to identify the best way to allocate health resources or to 
optimize health budgets, iii) to avoid or overcome inefficiencies of many countries in gaining 
health conditions, iv) to base health policy on costs and effects of different health 
interventions, particularly in middle- and low-income countries, and v) to improve clinical 
practice guidelines (39). 
Despite the advantages set forth, some limitations remain, such as the inclusion of items in 
the costs and the way their prices are determined, e.g., the inclusion of out-of-pocket 
expenses and costs associated with informal health care and extra costs for the years of life 
gained thanks to an intervention. In addition, there is variability in implementing 
interventions in different contexts or regions, and the valuation that no effect is observed 
when health processes are interrelated. Other challenges in costing include classification, 
such as salaries, medicine, capital, management, planning, monitoring, or costs at the 
organizational level (i.e., national, district, or hospital level) (39). Some of the 
aforementioned limitations are overcome in this study, as assistance to control leishmaniasis 
in Colombia is standardized. Therefore, items related to direct costs are also standardized. 
Regarding pricing, national standard sources were used, and an uncertainty analysis was 
performed by taking the percentage increase handled for the procurement of services in 
Institutions Providing Health Services (IPS). 
In addition, from a social perspective, it would be relevant to include non-medical costs 
associated with transportation to the IPS or to the place of treatment, out-of-pocket expenses 
for outpatient services, indirect costs associated with loss of productive activities of the 
patient and his or her family (due to the disease itself or to transportation to the place of 
treatment), among others, which would be much higher for systemic treatment compared 
with thermotherapy, as the former requires more medical visits and higher social costs 
associated with the treatment itself and the management of any adverse effects. In this 
respect, a cost-effectiveness assessment from a social perspective may improve 
thermotherapy outcomes for the treatment of cutaneous leishmaniasis. 
The main advantages of this study are that unlike other economic assessments, costing not 
only included analysis per patient and standard costing but also took actual monitoring data 
from a controlled clinical trial. This strategy allowed for overcoming constraints from 
previous studies that do not include the management of side effects, analyzing cost-
effectiveness regardless of the results of therapeutic safety (i.e., costs associated with the 
management of side effects) or taking clinical effectiveness data from observational studies. 
This study also took into account broad ranges of effectiveness, safety and costs, providing 
greater comprehensiveness to the model, as it represents different contexts, possible 
variations in outcomes attributable to the infecting species, the number, size and type of 
lesions, and the excellent internal and external validity of the clinical trial that was used for 
measuring effectiveness and safety. 
CONCLUSIONS 
The multiple benefits of thermotherapy, including its low cost, high safety and ease of 
implementation, show the relevance of its incorporation into the treatment of cutaneous 
leishmaniasis as a first-choice treatment. The excellent cost-effectiveness ratio of 
thermotherapy is a key feature for guiding decisions for disease management in Colombia 
and other countries with similar epidemiological patterns. The evidence generated in this 
study is useful for prioritizing interventions and public policies regarding this disease, 
efficiently allocating health resources and orienting researchers and professionals interested 
in this issue and mitigating costs generated by the disease for the Colombian System of Social 
Security in Health (Sistema de Seguridad Social en Salud). 
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Table 1. Costing protocol of patients treated with pentavalent antimonials. 
  L # Unit cost * Total* 
Glucantime: approximately 70 ampules 1.00 121 2.37 20 060.5 
Nurse (treatments): 20 applications 1.00 121 7.34 17 770.4 
Medical consultation: 5 visits 1.00 121 12.41 7 508.4 
Paraclinical tests         
Creatinine: 3 times 1.00 121 5.79 2 102.3 
BUN: 3 times 1.00 121 4.14 1 501.7 
AST/ALT: 3 times 1.00 121 18.00 6 532.5 
Amylase: 3 times 1.00 121 6.72 2 440.3 
CBC: 3 times 1.00 121 15.00 5 443.7 
ECG: once 1.00 121 16.96 2 052.3 
Side Effects         
Myalgia 0.55 67 0.71 47.6 
Arthralgia 0.54 65 0.71 46.2 
Headache 0.43 52 0.71 36.9 
Abdominal pain 0.02 2 1.77 3.5 
Fever 0.24 29 0.71 20.6 
Vomiting, Nausea, Anorexia, Diarrhea 0.74 90 2.73 245.8 
Infection of the lesion 0.04 5 44.06 220.3 
Effects in kidney 0.01 1 9.93 9.9 
Pancreatic effects 0.20 24 6.72 161.3 
Effects in Liver 0.17 21 18.00 377.9 
Hematological effects 0.12 15 15.00 224.9 
Total Standard Costing 66,807.2 
Average cost with Standard costing 552.1 
Rescue therapy I: 18 patients, to whom the same protocol was applied. 
Rescue therapy II: 1 patient 
TOTAL COST Costing per patient 76 521.6 
AVERAGE COST Costing per patient 632.4 
     
L: Likelihood of development. * US dollars, exchange rate $1 = $1,900 COP. 
 
  
Table 2. Costing protocol of patients treated with thermotherapy. 
  L # Unit cost 
* 
Total * 
ThermoMed 1.00 134 22.55 3 021.1 
Medical consultation: 5 visits 1.00 134 12.41 8 315.1 
Nurse (treatments): 2 visits 1.00 134 7.34 1 968.0 
Side Effects          
Myalgia 0.03 4 0.71 2.8 
Arthralgia 0.02 3 0.71 2.1 
Headache 0.10 13 0.71 9.2 
Abdominal pain 0.00 0 1.77 0.0 
Fever 0.03 4 0.71 2.8 
Vomiting, Nausea, Anorexia, 
Diarrhea 
0.10 13 
2.73 35.5 
Infection of the lesion 0.08 11 44.06 484.6 
Effects in kidney 0.01 2 9.93 19.9 
Pancreatic effects 0.05 7 6.72 47.1 
Effects in Liver 0.05 7 18.00 126.0 
Hematological effects 0.02 3 15.00 45.0 
Total Standard Costing 14,079.2 
Average cost with Standard costing 105.1 
Rescue therapy I: 48 patients, to whom the Glucantime protocol (Table 1) was 
applied 
TOTAL COST Costing per patient 39,981.6 
AVERAGE COST Costing per patient 298.4 
     
L: Likelihood of development. US dollar exchange rate $1 = $1,900 COP. 
 
  
Table 3. Synthesis of the analyses of effectiveness and costs of treatments. 
    Pentavalent 
antimonials 
Thermotherapy 
Effectiveness of the 
PECET Study 
Mean 85.1% 64.2% 
Minimum 78.4 55.7 
Maximum 91.9 72.7 
Effectiveness Meta-
analysis 
Mean 70.6% 73.2% 
Minimum  6.17 69.6 
Maximum 74.1 76.7 
Costs according to 
safety results * 
Mean $66,807.2 $14,079.3 
Minimum 66,257.4 13,572.1 
Maximum 67,529.3 14,684.3 
Costs according to 
procurement prices 
in Colombia * 
+ 25% 83,509.0 17,599.1 
+ 30% 86,849.4 18,303.0 
+ 48% 98,874.7 20,837.3 
* US dollars, exchange rate projected for 2013 of $1 = $1,900 COP. 
  
Table 4. Cost-effectiveness ratio and sensitivity analysis. 
  Pentavalent 
antimonials * 
Thermotherapy * 
Average cost-effectiveness ratio (standard costing) 785.0 219.3 
Sensitivity analysis  Range 
Univariate analysis for costs depending on safety analysis 778.6-793.5 211.4-228.7 
Univariate analysis for procurement costs in Colombia 981.3-1161.9 274.1-324.6 
Univariate analysis for effectiveness of the PECET study 727.0-852.1 193.7-252.8 
Univariate analysis for Meta-analysis effectiveness 872.2-972.4 181.0-201.1 
Multivariate analysis 721.0-1274.8 186.7-390.2 
      
Average cost-effectiveness ratio (costing per patient) 632.4 298.4 
Sensitivity analysis Range 
Univariate analysis for costs depending on safety analysis 627.34-641.6 292.0-306.3 
Univariate analysis for procurement costs in Colombia 784.2-948.7 365.0-453.3 
Univariate analysis for effectiveness of the PECET study 595.9-668.7 252.4-344.1 
Univariate analysis for Meta-analysis effectiveness 678.4-721.1 224.9-267.0 
Multivariate analysis 590.7-721.1 246.6-352.2 
Incremental Cost-Effectiveness Ratio 2523 
Sensitivity analysis Range 
Univariate analysis for costs depending on safety analysis 2,521-2,528 
Univariate analysis for procurement costs in Colombia 2,904-4,064 
Univariate analysis for effectiveness of the PECET study 2,323-2,746 
Univariate analysis for Meta-analysis effectiveness -40,560;-43,940 
Multivariate analysis 2,323-4,073 
   
* US dollars, exchange rate $1 = $1,900 COP. 
 
